Key Findings:  Preclinical evidence shows that cannabidiol (CBD) effectively decreases the production of inflammatory markers and cytokines and reduces tissue infiltration. CBD also appears to affect several other inflammatory reactions in immune cells. This information suggests CBD's therapeutic use to potentially alleviate a multitude of inflammatory and immune-related conditions.
Type of Study:  Meta-analysis
Study Result:  Positive
Research Location(s):  Italy
Year of Pub:  2023
Cannabinoids Studied:  Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Cannabinol (CBN), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), Cannabidivarin (CBDV)
Phytocannabinoid Source:  Unspecified
Chemotype:  Chemotype III
Receptors Studied:  CB1, CB2, GPCR 55, Opioid Receptor Mu , Opioid Receptor Delta, TRPA1, TRPV1, TRPV2, TRPM8, PPAR - Gamma, TRPs, PPARs
Ligands Studied:  Anti-inflammatory cytokines, Serotonin, Pro-inflammatory cytokines
Citation:  Martini S, et al. Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance. Int J Mol Sci. 2023; 24:(unknown pages). doi: 10.3390/ijms24043125
Authors:  Martini S, Gemma A, Ferrari M, Cosentino M, Marino F